MELISSA BROWN: Open Payments
NPI 1346923596 · SULPHUR, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,064 in 146 payments from 16 companies in 2025. Trend: 2023 $317 · 2024 $1,206 · 2025 $3,064
Food & beverage: $3,052Education: $12
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $546 |
| ABBVIE INC. | 24 | $396 |
| Vanda Pharmaceuticals Inc. | 9 | $380 |
| Axsome Therapeutics, Inc. | 15 | $296 |
| Neurocrine BioSciences, Inc. | 9 | $281 |
| Teva Pharmaceuticals USA, Inc. | 11 | $279 |
| Alkermes, Inc. | 21 | $260 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $167 |
| Corium, LLC | 7 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $83 |
Products named: VRAYLAR, REXULTI, FANAPT, Auvelity, INGREZZA, ARISTADA, UZEDY, CAPLYTA.
Industry payments across LA — which companies pay providers there.
